12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · 08/27 17:06
Gainers
- Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million.
- Propanc Biopharma (NASDAQ:PPCB) stock increased by 121.44% to $2.37. The company's market cap stands at $2.4 million.
- VolitionRX (AMEX:VNRX) shares rose 57.13% to $0.53. The company's market cap stands at $4.8 million.
- Cypherpunk Technologies (NASDAQ:CYPH) stock rose 21.16% to $1.98. The company's market cap stands at $175.6 million.
- Hyperliquid Strategies (NASDAQ:PURR) stock moved upwards by 20.54% to $13.94. The market value of their outstanding shares is at $2.3 billion. The company's, Q4 earnings came out today.
- AEON Biopharma (AMEX:AEON) shares moved upwards by 20.03% to $0.3. The market value of their outstanding shares is at $12.5 million.
Losers
- BeyondSpring (NASDAQ:BYSI) shares declined by 15.0% to $0.59 during Thursday's regular session. The company's market cap stands at $28.3 million.
- Aprea Therapeutics (NASDAQ:APRE) shares fell 14.99% to $0.83. The market value of their outstanding shares is at $12.3 million.
- Apimeds Pharmaceuticals (AMEX:APUS) stock fell 13.05% to $4.0. The market value of their outstanding shares is at $6.9 million.
- Basel Medical Group (NASDAQ:BMGL) stock fell 12.56% to $5.19. The company's market cap stands at $9.2 million.
- Clinuvel Pharmaceuticals (NASDAQ:CUVL) stock declined by 11.31% to $6.78. The market value of their outstanding shares is at $385.4 million.
- HealthEquity (NASDAQ:HQY) stock fell 11.07% to $92.86. The market value of their outstanding shares is at $8.7 billion. As per the news, the Q2 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.